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In utero hematopoietic stem cell transplantation (IUHCT) is an attractive approach
and a potentially curative surgery for several congenital hematopoietic diseases. In
practice, this application has succeeded only in the context of Severe Combined
Immunodeficiency Disorders. Here, we review potential immunological hurdles for the
long-term establishment of chimerism and discuss relevant models and findings from both
postnatal hematopoietic stem cell transplantation and IUHCT.
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TERMINOLOGY
Central tolerance: An immune mechanism for specificity of the
immune response set up in the thymus. Functional central tol-
erance prevents T cells with a high affinity to “self” from exiting
into the periphery.
Peripheral tolerance: Immune protocols that mediate speci-
ficity of the immune response, other than central tolerance. All
the following can be considered peripheral tolerance:
Dominant tolerance: A tolerance mechanism that can override
other tolerance mechanisms such as Tregs (regulatory T cells)
or myeloid-derived suppressor cells with capacity to suppress
effector mechanisms of other cells.
Regulatory T cells: Specialized CD4+FoxP3+ T cells that
inhibit proliferation and effector functions of other immune
cells via several mechanisms. Most studied for their effect on
CD8+ T cells but potentially also important for regulation of
other effector cell types.
Clonal deletion in reference to exhaustion: A type of terminal
differentiation in T cells (CD4 and CD8) elicited by continu-
ous presence of antigen. T cells gradually lose functionality in
a stepwise, strictly controlled process and sometimes die as a
function of continued antigen presence. Partial exhaustion is
sometimes reversible.
Anergy: Unresponsiveness of T cells previously stimulated
with their cognate antigen in the absence of an appropriate
second signal. Anergic T cells do not execute normal effector
function.
In utero hematopoietic stem cell (HSC) transplantation is not
a standard clinical approach, but with greater understanding of
the immune system and its development, as well as the disease
processes that are optimally treated in utero, the procedure
may become more widely used. Stem cell transplantation,
as any other transplantation is subject to potential rejection
reactions by the hosts’ immune system that recognizes the tissue
antigens of a different genetic makeup as “foreign” and elicits
an immune attack. This attack, if not properly controlled by
immune-suppressants, can lead to graft damage and ultimately
graft loss. Transplantation of hematopoetic stem cells in utero
seeks to take advantage of the early developmental stages of the
fetal immune system and elicit a dampened immune rejection
or perhaps achieve full graft tolerance. While attractive in
theory, the practical outcomes of in utero hematopoetic stem
cell transplantation have been disappointing for a multitude
of reasons. Here we review the complex issues pertaining the
immune system that have bearing on in utero hematopoetic stem
cell transplantation for a general clinical audience.
CENTRAL AND PERIPHERAL TOLERANCE
The main function of the immune system is to fight off infec-
tion of a huge variety of pathogens. To successfully fight “for-
eign” invaders without damaging the host, the immune system
has to sort through enormous antigenic diversity to recognize
the difference between “self” vs. “non-self.” Allogeneic trans-
plants (solid-organ and cell transplants) are not “self” from the
recipient perspective and hence are attacked by the recipient
immune system (allorejection) necessitating the administration
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of immunosuppressants. However, successful HSC transplants
will actively participate in the immune system as they give rise
to all white cells. Additionally, the special situation of HSC
transplantation in the context of the fetal immune system dur-
ing IUHCT warrants specific considerations of the developing
recipient environment to ensure graft survival.
Several fundamentally different processes establish necessary
self-tolerance and are also involved in (allogeneic) graft-tolerance:
central tolerance, exhaustion/peripheral deletion and regulatory
T cells (Treg).
Central tolerance results from deletion of self-reactive T cells
in the thymus (Rothenberg, 1992). This form of tolerance pre-
vents cells that are stimulated by a self-antigen from migrating
into the periphery where they can cause autoimmune damage,
and defines the immunological “self,” resulting in a state of “igno-
rance” to self-antigens. Ex vivo stimulation of a central tolerant
T cell population with self-antigens does not result in activation
or proliferation. Central tolerance is effective but not complete
and a few self-reactive T cells can migrate into the periphery
despite a functioning central tolerance mechanism (Griesemer
et al., 2010). Largely, these self-antigen-specific T cells do not
exert autoimmune function in the periphery because they are
suppressed by a T cell population which inhibits immune effec-
tor functions, the Tregs (Takahashi et al., 1998; Sakaguchi, 2003).
A population of cells that is tolerant only because of Tregs is stim-
ulated by self-antigen but so are the inhibitory Tregs that prevent
self-reactive effector functions. Hence, Tregs establish a state of
“active tolerance” toward an antigen. Ex vivo stimulation of this
cell population with self-antigen also does not result in activa-
tion or proliferation. However, when Tregs are depleted in mixed
lymphocyte culture systems, stimulation with self-antigen results
in activation and proliferation of self-reactive T cells (essentially
an “unmasking” of previously inhibited responses). While cen-
tral tolerance and T regs both mediate non-reactivity to self, the
mechanisms by which tolerance is established are very differ-
ent. There is another distinction between the two mechanisms:
Central tolerance is dependent on localization to the thymus
while Tregs are mobile, and when transferred to another host,
can and will perform appropriate suppressive function if properly
stimulated and maintained (Asseman et al., 2000).
Another mechanism that results in a non-reactive T cell pool is
T cell exhaustion. T cell exhaustion occurs when T cells are chron-
ically exposed to antigen under inflammatory conditions. Over
time, these T cells lose the ability to provide effector functions and
die. T cell exhaustion has been observed in persistent infections
and has been postulated as a mechanism by which alloreactive
T cells decline in functionality and are deleted in solid-organ
transplants.
In classical in vitro mixed lymphocyte reactions (MLR) all
the mechanisms discussed above result in non-reactivity of the
responder T cells (Figure 1). But that result is misleading in that
additional experiments (some of which are technically challeng-
ing) can unmask activity of T cells in these “negative” MLR
studies. These studies are really controls needed to interpret
results of engraftment protocols with confidence, especially since
the protocols are often not standardized, and use very different
models, time points, cell sources etc. The absence of follow-up
studies also highlights the problems in reproducing results or
adapting protocols from one model system to another.
THE MECHANISM OF CENTRAL TOLERANCE
Hematopoietic progenitor cells mature in the thymus, and then
are selected to generate a functional, self-tolerant peripheral T
cell pool. The outer region (cortex) of the thymus supports the
early stages of T cell development, when thymocytes are selected
for ability to interact with self-MHC molecules. Cells that sur-
vive this positive selection process travel on to the inner thymus
(medulla), where negative selection against self-tissue-specific
antigen recognition takes place (self -peptide-tolerance).
THYMIC DEVELOPMENT
Lymphoid progenitor cells migrate during embryonic develop-
ment in several discrete waves, coordinated with organogenesis
(Le Douarin, 1973; Le Douarin and Joterau, 1975). The E11.5
murine embryonic thymus receives a first influx of a small
number of lymphoid progenitor cells (Owen and Ritter, 1969;
Fontaine-Perus et al., 1981; Liu et al., 2005; Foster et al., 2008).
In humans, the thymus appears roughly 8 weeks after conception
at which time the first T cell progenitors originating from the fetal
liver and later from the bone marrow migrate into and colonize
it (Haynes et al., 1989). By week 10, 95% of the human fetal thy-
mus are lymphocytes (Fernandez and de Alarcon, 2013). In mice,
a model that is widely applied in studies of immune development,
only small numbers of T and B cells can be found at parturition
and the division of the spleen into T-cell and B cell zones (red
and white pulp) only occurs in the first week after birth (Burns-
Naas et al., 2008). In contrast to this, in humans, small numbers
of T and B cells can be found at the end of the first trimester while
splenic demarcation occurs at the beginning of the third trimester.
The thymus is composed of cells of stromal and hematopoietic
origin such as mesenchymal cells, thymic epithelial cells (TECs),
endothelial cells, and dendritic cells. Thymic epithelial cells are
the main cell type interacting with and providing selective clues
to T cells (Figures 2, 3). Based on location in the thymus, TEC are
characterized as cortical TEC (cTEC) or medullary TEC (mTEC).
Both arise from a common progenitor during thymic organo-
genesis (Rossi et al., 2006) and, if undisturbed, this progenitor
pool continues to support TEC generation and homeostasis in
postnatal life (Bleul et al., 2006).
HOW DO TECs SHAPE THE T CELL POOL?
Initial stages of T cell selection ensure that the resulting pool
can successfully “communicate” with cells of the host. To ensure
proper communication, T cells must be equipped to engage in
productive interactions with proteins that constitute the commu-
nication system, the MHC proteins. The cortical thymus selects
for this function in a process termed positive selection: T cells
with low-affinity interaction of T cell receptors with peptide-
MHC complexes receive survival signals while T cells with no or
too low affinity engagement die by neglect (Starr et al., 2003).
Importantly, T cells with too high an affinity for MHC are also
deleted as potentially damaging self-reactive players. Thymocytes
travel to the medulla where they interact with mTEC and den-
dritic cells that present self-antigens under the control of the
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FIGURE 1 | Mixed Lymphocyte Reactions (MLR) with central tolerant or
peripheral tolerant lymphocyte populations from IUHCT graft recipients.
Recipients of IUHCT carry mixed hematopoietic chimerism. (A,B) In central
tolerance, thymic selection will only allow recipient T cells that are
non-recipient and non-donor specific to persist (yellow/green cells). Similarly,
donor cells are only allowed to persist if they are non-recipient and non-donor
specific (blue/yellow cells). Exposure of these two responder populations to
irradiated donor cells will not elicit a proliferative response (A) even after the
deletion of Tregs (B). (C,D) In peripheral tolerance, recipient T cells with
specificity for the donor are allowed to progress through thymic selection into
the periphery (Green/blue cells) but effector functions and proliferation are
inhibited by Tregs (Green/pink cells). Exposure of these three responder
populations to donor cells will not result in proliferation (C). After the deletion
of Tregs, the recipient T cells with donor specificity will proliferate vigorously
in response to donor cells (D). Note: It is unknown whether the Tregs are
donor-derived or recipient-derived or both.
Autoimmune regulator gene (Aire) (Laan and Peterson, 2013).
Thymocytes reactive to presented self-antigens are deleted as
potentially self-reactive T cells (also affinity dependent). The T
cells reside in this environment for 4–5 days until they are released
to the periphery.
THE THYMIC DEFINITION OF “SELF”
The repertoire of self-antigen available for thymic selection is of
critical importance as it ultimately defines T cells as self-reactive
or not self-reactive. The diversity of this peptide pool is ensured
by a remarkable heterogeneity of thymic antigen-presenting cells
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FIGURE 2 | Cortical thymic T cell selection. (A) Chimeric bone marrow
can give rise to multiple blood products from the two stem cell sources
(recipient: green, donor: blue) such as antigen-presenting cells (APC) and
thymocytes (B) In the thymic cortex, productive interaction with the MHC
takes place. Though knowledge is limited, cortical Thymic Epithelial Cells
(cTEC) likely will be recipient-derived (C–F, green cTEC cell). In contrast,
APC are constantly turned over and immigrate from the periphery
theoretically allowing for the participation of donor-derived APC in the
thymic selection process (D,F). Therefore, donor thymocytes can interact
with recipient cTEC and recipient APC and hence recipient MHC to receive
survival signals (C) or with recipient cTEC and donor APC hence
interacting with donor APC (D) Conversely, recipient thymocytes can
interact with recipient cTEC and recipient APC and hence recipient MHC
to receive survival signals (E) or with recipient cTEC and donor APC hence
interacting with donor APC (D) The source of the peptides during this
process (recipient or donor) is unknown.
(APC) and the utilization of unconventional molecular pathways
by APC. These pathways ensure unique self-peptide repertoires
for both the negative and positive selection steps, with peptides
derived from the thymus itself, from the periphery and dif-
ferent developmental stages, including some from stages other
than the current developmental state. This remarkably diverse
repertoire is ensured by (1) promiscuous gene expression by
mTEC, (2) specific antigen processing features including pro-
teasome composition and protease sets, (3) intracellular anti-
gen sampling via autophagy of thymic epithelial cells and (4)
extracellular antigen sampling provided by immigrating dendritic
cells (DC) that sample the periphery. mTEC express hundreds
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FIGURE 3 | Thymic medullary selection. In the second step of thymic
selection, T cells are selected for the absence of high affinity
self-peptide-self-MHC reactivity. Chimeric bone marrow (A) can give rise to
multiple blood products from the two stem cell sources (recipient: green,
donor: blue) such as antigen-presenting cells (APC) and thymocytes
(B) While the Medullary Thymic Epithelial Cells (mTEC) are recipient
derived (green mTEC, C), medullary APC can be either recipient derived
(green, left) or donor derived (blue, right) and all of these cells can either
present recipient (green) or donor derived (blue) peptides on their
respective MHC. Combined with thymocytes of either recipient or donor
origin, several combinations of MHC-peptide-TCR reactivity are possible (D)
of which those with high affinity will be deleted (E) intermediate reactivity
will develop into tTregs and low affinity will develop into conventional T
cells of the CD4 or CD8 lineage.
of self-antigens that are otherwise expressed only in strictly
regulated spatial or temporal contexts. In mTEC, proteins are
translated for the sole purpose of undergoing degradation, after
which they are loaded onto MHC molecules. Regulation of this
complex and unique process is still poorly understood but the
recent discovery of the transcriptional regulator Aire has shed
some light on this process (Anderson et al., 2002). Aire defi-
ciencymanifests with autosomal recessive inheritance pattern and
causes a polyglandular disorder that classically manifests as spon-
taneous autoimmunity against the parathyroid and/or adrenal
glands, and/or by a mucocutaneous candidiasis infection (termed
Autoimmune polyendocrinopathy–candidiasis–ectodermal dys-
trophy (APECED), also known as autoimmune polyendocrine
syndrome–type 1 (APS-1) (Bjorses et al., 1998; Rosatelli et al.,
1998; Scott et al., 1998). Aire, amongst other functions, controls
the expression of tissue antigens (as detailed above in 1) and
regulates intrathymic DC positioning via Aire-dependent XCL1-
expression (Lei et al., 2011). In mice, the first Aire + mTEC
subsets can be observed at around embryonic day E16 and hence
precede the formation of fully mature thymocytes (Zuklys et al.,
2000; White et al., 2008). In humans, the kinetics by which
APECED- associated autoantibodies appear in pediatric patients
suggest onset of Aire-mediated self-tolerance at or before birth
(Wolff et al., 2013).
Macro-autophagy enables mTECs to present intracellular
cargo onMHC II molecules (Nedjic et al., 2009). Resident thymic
DC’s are known to sample and cross-present mTEC-derived
antigens and blood-borne antigens (Klein et al., 2009).
Additionally, about 50% of thymic DC are immigrating DC that
already sampled the periphery and imported peripheral peptide
cargo. Antigen presentation occurs in two important steps—
processing of proteins into MHC-binding peptides and binding
of a peptide to an MHC complex. Peptides destined for loading
onto MHC class I are generated by the proteasome, a multipro-
tein complex that executes protein degradation processes depen-
dent on the inflammatory milieu. The housekeeping proteasome
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generates peptides from proteins under non-inflammatory con-
ditions and the immunoproteasome under inflammatory condi-
tions (Kloetzel and Ossendorp, 2004). Thymic DC and mTECs
express a mixture of both types of proteasomes and thus present
both partly non-overlapping peptide pools but with careful exclu-
sion of pathogen-associated molecules (Nil et al., 2004; Bonasio
et al., 2006; Hadeiba et al., 2012). MHC class II binding pep-
tides are generated in the endosomal/lysosomal compartment
by a mixture of proteases including those of the thymus, again
mirroring the enormous complexity presented to the developing
immune system (Gommeaux et al., 2009).
MECHANISMS OF PERIPHERAL TOLERANCE
REGULATORY T CELLS (TREGS)
Thymic selection is a highly efficient process but it is not perfect.
It is now accepted that self-reactive T cells escape the deletion
process and circulate in the periphery. The reason self-reactive
T cells do not cause pathology is that they are suppressed by
regulatory T cells (Tregs), a subset of CD4+ T cells defined by
intranuclear expression of the transcription factor FoxP3. Thymic
Tregs (tTregs) develop during thymic T cell selection from CD4+
clones withmoderate-to high-affinity for self-antigens. Peripheral
Tregs (pTregs) arise from mature, naïve CD4+ T cells in the
periphery when they encounter antigen under certain conditions
(Curotto de Lafaille and Lafaille, 2009). Peripheral induction of
pTregs is thought to require TCR stimulation of naïve CD4+ T
cells in the presence of TGF-β and IL-2 and occurs in the tissues
(Chen et al., 2003; Mucida et al., 2007; Curotto de Lafaille and
Lafaille, 2009) rather than the circulation. For example, most of
the pTregs important for mucosal tolerance to environmental and
food antigens are induced in the gut (Faria and Weiner, 2006a,b).
Despite the fact that tTregs essentially follow the same
ontogeny as effector T cells, the TCR repertoires of Tregs and
conventional T cells are distinct with only limited overlap (Hsieh
et al., 2004; Pacholczyk et al., 2006). Although there are still many
open questions about tTreg development, an amount of self-
reactivity below the threshold for negative selection is likely an
important factor driving Treg lineage commitment (Hsieh et al.,
2012). The contribution of different populations of APC to tTreg
formation was explored in a series of studies utilizing geneti-
cally engineered mice. Transfer of MHC II–sufficient or MHC
II-deficient bone marrow cells into irradiated RAG-1 deficient
mice resulted in comparable frequencies of tTregs generated, sug-
gesting that bone-marrow derived APC are dispensable for tTreg
induction (Liston et al., 2008). In turn, experiments in which
irradiated mice genetically devoid of co-stimulatory molecules
were reconstituted with wild-type bone marrow, tTreg frequency
was again unaffected suggesting that bone-marrow derived APCs
are capable of tTreg suppor (Proietto et al., 2008; Spence and
Green, 2008). Of note, the expression of “normal” TCR diversity
and function in tTreg populations generated under these artificial
experimental conditions has not yet been fully investigated.
Human fetal tissues in the second trimester display a signif-
icantly increased frequency of Treg compared to other devel-
opmental stages and locations; the lymph nodes contain about
15–20% of these cells (compared to about 5% in other locales
and time points) (Cupedo et al., 2005; Michaelsson et al., 2006).
Interestingly, this Treg abundance is not true for the fetal thymus
at the same time suggesting that the peripheral fetal Treg either
originated from nTreg that expanded in the periphery or that
they are iTreg (Burt, 2013). Elegant experiments by Mold et.
al. demonstrated that these fetal Treg arise in response to Non-
Inherited Maternal Antigens (as further discussed below) and
unveiled a general propensity of the fetal immune system to react
toward and antigenic challenge with the induction of Treg medi-
ated tolerance (Mold et al., 2008). These observations have led
to some speculation about a potential contribution to fetal and
neonatal increased sensitivity to infections (increased severity and
infections with pathogens that are usually considered commen-
sal flora in adults) and less effective immunization by vaccines
(Mold et al., 2008). Importantly, the emerging picture points
toward the fact that the human fetal immune system is not inert,
non-developed or immature but instead highly active generat-
ing tolerogenic responses as further detailed in the model of the
layered immune system (Mold et al., 2008).
T CELL EXHAUSTION
T cell exhaustion has been observed in many chronic infections
and cancer. It is a state in which T cells exhibit poor effector func-
tions, and express inhibitory molecules and a transcriptome dis-
tinct from that of functional effector or memory T cells (Wherry,
2011). Exhaustion is best described for persistent infections with
high levels of viral replication such as the human immunodefi-
ciency virus (HIV), or hepatitis C virus (HCV). In those settings,
CD8+ T cells lose effector functions in a distinctive hierarchical
manner starting with proliferative capacity, IL-2 production, then
killing capacity. Severely exhausted (end-stage) cells are unable to
degranulate at all and are eventually deleted (Moskophidis et al.,
1993; Zajac et al., 1998; Wherry et al., 2003). The precise features
of exhaustion seem to vary between infections but in general, low
CD4+ helper cells and high viral replication are correlated with
greater exhaustion of the CD8+ T cell pool in humans (Wherry
and Ahmed, 2004; Blattman et al., 2009; Virgin et al., 2009). In
both solid-organ and HSC (including IUHCT) transplantation,
the recipient and donor alloantigens are continuously present and
hence can potentially induce exhaustion of alloantigen-specific
T cells. In fetuses or neonates, exhaustion has thus far not been
observed possibly due to the tolerogenic propensity in human
fetuses (discussed above).
WHAT TYPES OF TOLERANCE MECHANISMS HAVE BEEN
OBSERVED IN IUHCT TRANSPLANTATION?
In the case of iatrogenic solid organ allotransplants, tolerance is
defined as donor-specific hyporesponsiveness in the absence of
pharmacologic immunosuppression (Fung, 1999). Operational
tolerance has been reported for different types of transplanta-
tion but the underlying mechanisms are not fully understood.
In IUHCT and HSC transplantation, graft failure or dimin-
ished/disappearing chimerism can be due to two factors or a
combination thereof: (1) loss of HSC or their differentiation
products due to lack of engraftment or (2) immunorejection of
otherwise established, healthy HSC or their differentiated prod-
ucts. Some mechanisms that were elucidated in solid organ or
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HSC transplantation may apply to IUHCT and will be discussed
in this context.
IN UTERO TOLERANCE ESTABLISHMENT, THE EXPERIMENTS OF
BILLINGHAM, BRENT AND MEDAWAR
In 1953, Billingham, Brent, and Medawar conducted a series of
experiments to test the hypothesis that “mammals and birds never
develop, or develop to only a limited degree, the power to react
immunologically against foreign homologous (as allografts were
known then) tissue cells to which they have been exposed suf-
ficiently early in fetal life” (Billingham et al., 1953). Skin grafts
between adult mice of two different strains normally result in
rejection after about 11 days. In the 1953 study, mouse pups age
E15 or 16 (term is day 21) were inoculated with adult tissue from
another strain. Five littermates were born to which skin from the
same strain as the in utero inoculant was grafted. The grafts were
rejected by two, accepted long-term in two and accepted only
short-term in one recipient. This experiment demonstrates that
transplant rejection can be ameliorated by in utero exposure to
adult allogeneic tissues. However, grafting these mice tolerant to
one strain with skin from yet another strain did result in rejection,
demonstrating that the acquired tolerance was indeed specific.
Lastly, they used themice tolerant to the skin graft and transferred
cells from a mouse of the same strain that was immunized against
the same skin graft into these recipients. They found that these
previously tolerant mice now rejected the graft, the tolerance was
“broken.” Despite much deeper understanding of immunoregula-
tion today, it is still unclear which tolerance mechanism/s were at
work in these experiments byMedawar and colleagues (Figure 1).
THE THYMUS IN IUHCT TRANSPLANTATION
Donor-derived APC transplanted as passenger leukocytes are
known to play an important role in early graft recognition and
graft loss in solid organ transplantation. This type of antigen
presentation is termed direct presentation and will stimulate T
cells that can productively interact with the donor-MHC-peptide
combinations present on the donor APC. The role of direct pre-
sentation diminishes over time as the passenger APC die off. In
contrast to solid organ transplants, HSC transplants will con-
tinuously generate donor APC over the lifetime of the graft. At
later times after solid organ transplantation, rejection is triggered
by a process termed indirect presentation and refers to the pre-
sentation of donor(allo)-peptides by recipient APC. This type of
presentation will be continuously functional throughout the life-
time of the graft, as recipient APC circulate and pick up antigen.
First observed in solid-organ transplantation, the kinetics and
contribution of direct vs. indirect antigen presentation pathways
are much less understood in HSC transplantation and IUHCT.
In animals or humans with mixed bone-marrow chimerism,
both donor and recipient HSC can theoretically give rise to the
different blood products of all blood lineages. To generate periph-
eral T cells, donor T cells must be positively and negatively
selected in the thymus (Figures 2, 3). The establishment of tTreg-
mediated tolerance to the donor can follow different scenarios.
As mentioned above, the APC compartment of both the thymic
cortex and medulla is in constant turnover with peripheral APC
migrating in and new resident APC differentiating locally. If the
recipient has hematopoietic chimerism after IUHCT, both APC
populations can be either donor-derived or recipient-derived
(Figures 2, 3). Additionally, these APC sample blood-borne
antigens that can also be donor- or recipient-derived. Under
these conditions, the selection of both effector T cells as well as
tTregs from both sources of HSC that recognize both the host
and the donor as “self” is theoretically possible. This scenario
would establish a two-way tolerant state, utilizing mechanisms of
both clonal deletion and tTreg generation. Indeed, in a mouse
model of IUHCT, both donor (direct presentation) and recip-
ient APC (indirect presentation) were found to participate in
antigen presentation and both induced clonal effector cell dele-
tion in the thymus (Nijagal et al., 2013). Interestingly, deletion
was also detected in the spleens of animals that did not develop
chimerism indicating that transient antigen presence is sufficient
for the development of central tolerance.
In a SCID patient with a haploidentical fetal liver and thy-
mus transplant, T cell clones were established after 11 years of
healthy life of this patient (no indications of GVHD) (Roncarolo
et al., 1988). B lymphocytes were found to be of recipient origin
while the T cells were of donor origin. Of the 50 established T
cell lines, 15 displayed recipient reactive proliferative and cyto-
toxic responses (6 CD4+ T cell lines and 9 CD8+ T cell lines)
demonstrating that clonal deletion of host-reactive T cells is not
complete in this patient. In subsequent SCID patients trans-
planted with either haploidentical bonemarrow or fetal liver stem
cells, donor-anti-recipient MLR were non-reactive but again,
host-reactive donor T cell clones were isolated (Bacchetta et al.,
1993, 1995). However, these effector cells, especially the CD4 T
cell clones, displayed reduced cytokine production capabilities
and reduced proliferative capacity compared to non-transplanted
donor cells. These observations suggest a Treg-mediated suppres-
sion of T cell reactivity in vivo and in MLR accompanied by
an exhaustion mechanism that limits reactivity of the recipient-
reactive donor cells that escape thymic selection.
REGULATORY T CELLS IN IUCHT TOLERANCE
In a murine IUHCT model, a higher proportion of Tregs was
observed in animals that retained chimerism vs. animals that did
not retain chimerism or were not subject to IUHCT (Merianos
et al., 2009). The authors speculate that a similar mechanism that
leads to fetal Treg induction in response to trafficking maternal
cells would be responsible for the observed increase in animals
with chimerism. However, in this study, the origin of Tregs (donor
or recipient derived) was not further addressed. That question
was addressed in a study utilizing breeding schemes of T cell
transgenic animals to explore the role of direct vs. indirect pre-
sentation after IUHCT (Merianos et al., 2009; Flutter et al., 2010).
Similar to the finding of the previous study, both with direct and
indirect presentation, the percentage of donor-derived Tregs in
the thymus and spleen was significantly increased. However, the
absolute numbers of Tregs were not increased but instead the
skewed proportions were due to a decrease in effector T cells.
While these studies indicate that the donor cells are converted
to Tregs and contribute to the tolerogenic environment, whether
there is an increase in conversion to Tregs after IUHCT is still
somewhat unclear.
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T CELL EXHAUSTION/CLONAL PERIPHERAL DELETION IN IUHCT
TOLERANCE
Given that the key factors involved in T cell exhaustion—the
continued presence of antigen and inflammation—applies to
both solid organ and HSC/IUHCT transplantation, the role of
T cell exhaustion needs to be critically evaluated in this context
(Valujskikh and Li, 2012).
In IUHCT, the mechanism of T cell exhaustion would be in
play if clonal deletion of recipient-reactive donor cells in the thy-
mus is incomplete. In that case, exhaustion of recipient-reactive
donor cells would limit GVHD damage that these cells would
otherwise cause. Indeed, in SCID patients transplanted with
either fetal liver stem cells or haploidentical bone marrow cells,
recipient-reactive T cell clones displayed dysfunctional cytokine
production demonstrating both incomplete thymic clonal dele-
tion as well as T cell exhaustion of those reactive clones (Bacchetta
et al., 1993, 1995). Similarly, in a mouse model of IUHCT, partial
clonal deletion and absence of functional rejection of a donor skin
graft were observed (Kim et al., 1999). In that model, functional-
ity of the remaining donor-specific T cells could be re-established
after the addition of IL-2, indicating that these cells were indeed
partially exhausted, albeit this can only be determined with cer-
tainty in MLR with and without Treg depletion.
Information about the mechanism of T cell exhaustion can
be gleaned from the study of HSC transplantation in the setting
of chimerism with non-hematopoietic recipient cells serving as
potential APC is similar to IUHCT. Indeed, the antigenic source
responsible for donor T cell exhaustion was addressed in a mouse
model of allogeneic bone marrow transplantation. Here, a clin-
ical scenario of non-myeloablative transplantation and delayed
lymphocyte infusion was modeled (Flutter et al., 2010). Murine
recipients were lethally irradiated and reconstituted with mixed
bone marrow cells that included T cell-depleted host marrow
and T cell-depleted donor marrow with a partial MHCmismatch
and a congenic marker allowing identification. After reconstitu-
tion and recovery from lymphopenia, donor T cells were infused
which led to the elimination of host hematopoietic elements but
not to GVHD, modeling a graft-vs.-tumor effect (Figure 4). The
donor lymphocytes expanded vigorously up to day 12 and then
declined but even after day 60, 5–10% of peak numbers of these
alloantigen-primed cells persisted in lymph nodes. However, tests
of donor-host cytotoxic activity in vitro, showed reduced T cell
effector function, proliferative capacity, and IFN-γ production
by day 60. This observation of continued presence of donor cells
but reduced effector and proliferative capacity is strongly indica-
tive of classical exhaustion. The authors next inquired whether
persistent antigen expression by the recipient non-hematopoietic
compartment was responsible for donor cell exhaustion. To
address this, they performed a similar experiment as discussed
above utilizing a transgenic mouse strain that does not express
non-hematopoietic tissue antigen (minor HC) genes. In those
mice, stimulation of allo-responses occurs only via professional
APC while in wild-type mice, both professional APC and non-
professional cells such as endothelial cells can present antigen.
At day 60, cytotoxicity, recall responses, and memory forma-
tion were impaired in wild type mice experimentally. In contrast,
in mice devoid of minor HC genes in the non-hematopoietic
compartment, none of these features of exhaustion appeared and
host-reactive T cells remained fully functional even after 60 days,
suggesting that antigen presentation by non-professional APC is
responsible for allo-specific T cell exhaustion. These observations
strongly indicate that recipient-reactive donor T cells can escape
thymic clonal deletion but will acquire an exhausted phenotype in
the periphery due to continued presence of “their” antigen in the
context of non-professional antigen-presenting cells. The extent
to which this is the underlying explanation for T cell exhaustion
in the context of IUHCT remains to be determined.
IMMUNOLOGICAL BARRIERS TO IUHCT
Successful, long-term engraftment of HSC requires successful ini-
tial engraftment overcoming the barriers of host-competition,
immunological space availability, “receptivity” of appropriate
niches to support stem cells and possibly active rejection mech-
anisms. At later times, graft maintenance and functionality
requires both the continuous absence of active rejection mech-
anisms (or the presence of rejection that is low-level and does
not delete the graft) and successful participation of graft-derived
cells in the selection and maturation processes to form fully dif-
ferentiated cells. Failure of any of these requirements may limit
engraftment or lead to poor long-term graft function but the par-
ticipation of each of these components in the final phenotype
is sometimes difficult to assess. In IUHCT, the presence of the
maternal immune system adds another layer of complexity, the
effects of which are only partially understood.
FACILITATING HSC ENGRAFTMENT IN IUHCT
Current observations in IUHCT models suggest that success-
ful engraftment starts in the fetal liver from which the cells
migrate into the bone marrow. In mice, CXCR4 chemokines fol-
low an SDF-1a chemoattractant gradient for fetal-liver to fetal
bone marrow migration. Migrating HSC also express matrix
metalloproteinases (MMP-2 and MMP-9) at their leading cellu-
lar edge, facilitating degradation of extracellular matrix during
migration toward marrow, and they secrete collagen and metal-
loprotease inhibitors to modify the niche. Hematopoietic stem
cells used for IUHCT should express the necessary migratory
molecule repertoire and other factors of fetal liver HSC to allow
engraftment.
Facilitation of engraftment was further addressed in an
IUHCTmodel in which donor bone marrow was stimulated with
vascular endothelial growth factor and stem cell factor (Shaaban
et al., 2006). These cytokine-stimulations were chosen to pro-
vide a competitive advantage to the graft with regard to homing,
establishing residence, proliferation, apoptosis, and bidirectional
tolerance. This pre-treatment regimen resulted in higher ini-
tial chimerism rates and prolonged survival of skin allografts
but long-term engraftment remained unchanged. Expression
analysis of relevant homing receptors on the cytokine-treated
graft cells did not indicate any changes and host liver hom-
ing was not impacted by the treatment. The authors suggest
that early progenitor cell subsets did display enhanced hom-
ing which could have contributed to the temporary increase in
chimerism. They further conclude that cytokine pre-treatment
induced cell-cycle activation of normally quiescent progenitors
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FIGURE 4 | Graft-vs. host and host-vs. graft disease. Graft-vs. host disease
or graft-vs. leukemia effect is based on the same anti-host reactivity of the
graft lymphocytes (top panels). Recipient (green centers) and donor (blue
centers) cells undergo thymic selection, and donor T cells with recipient
specificity escape into the periphery (lowest row of top panel). These
recipient-reactive cells will delete leukemia cells and other host lymphocytes
in the periphery. In severe cases, graft-vs. host disease develops and recipient
tissues such as the kidney are attacked. The extent of recipient-specific
effector cells attacking recipient T cells already in the thymus or HSC in the
bone marrow is unknown. Host-vs. graft reactions (lower panels) are the basis
of graft rejection in which recipient T cells with donor specificity escape
thymic deletion and attack donor cells. While it is known that ultimately
disappear from the bone marrow in this case, it is unclear whether this is due
to direct deletion by donor-specific recipient cells or another mechanism.
leading to rapid expansion of donor hematopoiesis and increased
early chimerism. These observations further underline the impor-
tance of long-term monitoring of chimerism in these models
and the fundamental disconnect between early engraftment and
chimerism and its long-termmaintenance. In a series of follow-up
experiments, competitive advantage of the graft was achieved by
experimental inhibition of CD26 expression in a mouse model of
IUHCT (Peranteau et al., 2006). CD26 is a peptidase that cleaves
SDF-1a and thereby inhibits its chemoattractant effect on HSC.
Blocking of CD26 in IUHCT of bone marrow or enriched HSC
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resulted in increased homing to the fetal liver, and an increased
frequency of animals that developed chimerism with increased
levels and prolonged stability.
SELF-ANTIGEN AND T CELL HOMEOSTASIS IN DIFFERENT IUHCT
APPLICATIONS
Homeostatic maintenance of T cells requires the interaction with
self-MHC loaded with self-antigen and γ chain cytokines. T cells
need to interact with self-MHC of the appropriate class loaded
with self-peptide to maintain a tonal TCR signal that ensures
T cell survival (Jameson, 2002). Under lymphopenic conditions
such as in a SCID fetus or after anti-thymocyte treatment, naïve
T cells not only survive but proliferate until the “immunologic
space” is filled. This process of lymphopenia-induced expan-
sion also necessitates self-MHC self-peptide interactions (Bender
et al., 1999; Kieper and Jameson, 1999; Oehen and Brduscha-
Riem, 1999). Lymphopenia-induced expansion is limited by the
available “immunologic space,” physical space with the appropri-
ate microenvironment and resources such as APCs and cytokines
for which T cells compete (Ernst et al., 1999; Surh et al., 2000).
Restrictions of the immunological space ensure that the steady-
state size of the lymphocyte pool is stable and diverse. T cells
that expand in response to lymphopenia frequently change phe-
notype, and acquire the phenotypic and functional properties of
memory cells without transitioning through the typical effector
intermediates (Cho et al., 2000; Tchao and Turka, 2012). Further,
memory autoimmune cells are more resistant to immunodeple-
tion and will proliferate vigorously in response to lymphopenia,
resulting in a disproportionate enrichment of memory autoim-
mune cells (Monti and Piemonti, 2013). Considerably less is
known about the antigen sources used in self-peptide/self—MHC
presentation during homeostatic T cell interactions than is known
about the antigen sources used in thymic selection of T cells. Cell
death via apoptosis, an orderly process and an integral part of nor-
mal development, does not prompt an immunologic explosion.
In contrast, necrosis or the related necroptosis occurs in response
to starvation or membrane disruption and, despite production
of the same antigens as in apoptosis, does provoke the immune
system (Walsh and Bell, 2010; Lu et al., 2014). Thus, the pres-
ence of antigen does not absolutely imply its accessibility for a
given immunological process such as presentation of self-peptide
self-MHC in the steady-state homeostatic context.
POTENTIAL FETAL ADAPTIVE IMMUNE MECHANISMS OF REJECTION
Current protocols for IUHCT in dog and non-human primate
models use T-cell replete bone marrow for transplantation. In the
absence of this repletion, engraftment efficiency is greatly reduced
(Shields et al., 2003; Petersen et al., 2013; Vrecenak et al., 2014a).
These observations suggest that functional T cells are neces-
sary for efficient engraftment, possibly to suppress fetal rejection
responses or to create hematopoietic space, but these speculations
require further study.
Thymic T cell colonization begins 8–9 weeks after human con-
ception and by 10 weeks, T cells constitute >95% of the cells in
the thymus (Haynes et al., 1989). Similarly, B cells start to appear
in the omentum and fetal liver at 8 weeks post-conception and
in the fetal spleen at ∼11 weeks. By week 22, 70% of splenocytes
are lymphocytes. NK cells appear in human fetal liver at 5 weeks
after conception; at 6 weeks they constitute 5–8% and by 18
weeks 15–25% of fetal liver lymphocytes (Uksila et al., 1983;
Thilaganathan et al., 1993). They also constitute 10–15% of cord
blood lymphocytes. Alloreactive fetal lymphocytes (lymphocytes
that responded to in vitro exposure to allogeneic cells by pro-
liferating) are detectable in fetal livers as early as 7.5 weeks of
gestation, in thymus at 12.5 weeks, and spleen and blood at 14.5
weeks (Stites et al., 1974). T cell lines generated from fetal livers
demonstrate allo-reactivity (Renda et al., 2000a). Though limited
numbers of relevant studies have been reported, the complexi-
ties of the human fetal immune system are becoming increasingly
apparent from comparisons of transcriptional profiles of fetal
cells vs. adult cells, revealing fundamental differences (Mold et al.,
2010). These studies strongly suggest that phenotypic similar-
ity between fetal and adult immune cells might not extend to
functional similarity, and that functionality of fetal immune cells
deserves direct investigation. Currently, human fetuses after 14
weeks of gestation are considered immunocompetent with regard
to donor-rejection responses (Flake and Zanjani, 1999a,b; Renda
et al., 2000b).
In an elegant study, Mold et al. demonstrated fetal regulatory
T cell responses elicited by non-inherited maternal alloantigens
(NIMAs, Figure 5) (Mold et al., 2008). NIMAs are components
of the maternal genome, including MHC genes, not inherited
by the fetus. Fetal exposure to these antigens occurs via the
transplacental migration of maternal cells and can be detected
in multiple fetal organs as early as week 14 (Jonsson et al.,
2008). The presence of maternal cells raises the possibility of
fetal anti-maternal immune rejection and implies parallel devel-
opment of regulatory elements that limit rejection (reviewed in
Burt, 2013). Indeed, Tregs are fairly abundant in the human
fetus and the early fetal immune system seems skewed toward
tolerogenic responses until effector functions increase and dom-
inate at term (theory of the layered immune system in human
fetuses) (Herzenberg et al., 1992). Fetal tolerance of NIMAs
was postulated before it was demonstrated experimentally based
on epidemiological data showing that maternal donor organs
elicit less rejection than paternal donor organs (Burlingham and
Benichou, 2012). The conditions under which (semi)allogeneic
maternal cells induce fetal Tregs, are also not yet fully understood.
The constant, low number of immigrating maternal cells is clearly
different from IUHCT in which a large bolus of cells is delivered
at once, disrupting the normal cell number ratios and relation-
ships. Better understanding of this mechanism could be useful
in the development of protocols to induce Treg tolerance to the
IUHCT.
REJECTION BY FETAL INNATE IMMUNE MECHANISMS
The role of innate immunity in solid allograft and HSC rejec-
tion is poorly understood (Alhajjat et al., 2010; Loewendorf and
Csete, 2013). Human umbilical cord blood contains NK cells
with mature MHC responsive receptors suggesting that NK self-
recognition is functional before birth (Grzywacz et al., 2006;
Wang et al., 2007). Insights into the role of innate immunity in
IUHCT were gleaned from recent mouse studies in which thresh-
old levels of initial chimerism (>1.8%) were found to predict
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FIGURE 5 | Non-inherited maternal antigens (NIMAs). Central tolerance
includes tolerance toward antigens that the fetus inherited from both mother
and father (top panels). Maternal cells inhabiting the fetus bring along
additional antigens that were not inherited by the fetus (middle panel, left hand
side symbols on the maternal cell). The presence of these antigens induces
fetal Tregs specific for these NIMAs (middle panels, yellow cell on the right).
When donor cells carry NIMAs, these fetal Tregs will suppress allo-reactions
(lower panels), an effect that can be either detrimental or desirable.
long-term engraftment and correlated with a donor-tolerant NK
response (Durkin et al., 2008). NK depletion in animals with sub-
threshold chimerism resulted in abrogation of allograft rejection
and the establishment of chimeras. NK cell reactivity depends on
a delicate balance of activating and inhibitory receptors and in sta-
ble chimeras, the expression of the inhibitory NK receptor Ly49A
is down-regulated compared to animals in which chimerism was
lost. Initially, Ly49A expression was reduced in all recipients of
IUHCT albeit still higher in the animals that subsequently lost
chimerism indicating that those animals experienced an inad-
equate degree of receptor-ligand interaction resulting in failed
host NK-cell education during the time of receptor acquisition.
In a subsequent study, the transfer of donor MHC to host NK
cells (trogocytosis) was shown to correlate with NK cell tolerance
(Alhajjat et al., 2013).
MICROCHIMERISM vs. MACROCHIMERISM AND ITS ROLE IN
TRANSPLANT TOLERANCE AND IUHCT
Since the discovery of donor microchimerism in recipients
of solid-organ transplants by Starzl et al. donor leukocytes
that remain functional through the organ preservation process
and enter the host bloodstream were suspected mediators of
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transplant tolerance (Starzl et al., 1992; Hisanaga et al., 1995;
Hundrieser et al., 1995; Schlitt et al., 1995). Chimerism that is
not detectable by FACS but only with sensitive PCR methods is
generally referred to as microchimerism while macrochimerism
is chimerism at levels readily detectable by FACS. Donor
leukocytes can persist in the recipient for many years and
result in allogeneic microchimerism not unlike maternal-fetal
microchimerism (Verdonk et al., 2011). Stable levels of donor
microchimerism have been suggested as a marker of transplant
tolerance allowing reduction of immunosuppressive drug doses
(Ayala et al., 2009). One percentage microchimerism can be suffi-
cient for transplant tolerance in xenogenic animal models (Ildstad
and Sachs, 1984). These studies have prompted exploration of
chimerism as a tolerogenic mechanism, clinically accomplished
by transplantation of allogeneic bone marrow after appropriate
host conditioning (Trivedi et al., 2005). Nonetheless, the mecha-
nism of tolerance induced by microchimerism is not completely
clear. Early interpretations such as the theory of reciprocal dele-
tion and exhaustion of host and donor effector T cells were based
on the absence of donor-reactivity in in vitro MLR or killing
assays without taking the role of Tregs into account (Starzl et al.,
1994). Clinically, various types of chimerism levels from none to
high or temporary have been observed without clear correlation
to clinical rejection or operational tolerance (Billingham et al.,
2003).
In a mouse model of IUHCT, congenic adult bone marrow
was used for IUHCT followed by booster injections on days 2,
4, and 7 of life (Milner et al., 1999). The congenic setting ensured
that immunologic effects would not confound the observations.
Postnatally boosted animals had significantly higher levels of
donor cell engraftment as determined in the peripheral blood
6 weeks after birth and the increased levels were stable until
the last time point analyzed, 6 months of age. In a subsequent
study a booster transfer of allogeneic donor bone marrow was
applied after non-myeloablative total body irradiation (Peranteau
et al., 2002). In that study, low-level chimerism after IUHCT
was enhanced to high-level chimerism depending on the irra-
diation dose; the mechanism was found to be donor tolerance
by the host and a transient competitive advantage of the non-
irradiated donor stem cells. Lastly, no evidence of GVHD was
observed in these experiments, suggesting that this protocol of
prenatal tolerance induction in preparation for subsequent post-
natal treatments is a potential clinical strategy. Booster regimens
were also found to be possible in canine models, in 2 of the 5
boosted animals the degree of chimerism increased from <1%
after IUHCT to 35–45% after postnatal boost with busulfan con-
ditioning (Peranteau et al., 2009). In contrast, postnatal HSC
transplantation did not result in detectable chimerism in naïve
controls, demonstrating that IUHCT conditioning is crucial to
facilitate postnatal minimal conditioning HSCT. Importantly,
the phenotype of canine leukocyte adhesion deficiency (CLAD)
was ameliorated by the IUHCT serving as a proof of principle
that this lethal phenotype can be rescued by IUHCT. The rea-
son for the heterogeneous chimerism levels within one group
of experimental animals is unclear. Possibly, a certain threshold
microchimerism needs to be established via IUHCT to achieve
central tolerance which subsequently allows for the effective
postnatal boost but further studies are required to understand this
phenomenon.
A study refining the delivery method of IUHCT in the hap-
loidentical canine model recently achieved, for the first time,
long-term stable therapeutic levels of chimerism in a large ani-
mal model without prior conditioning or GVHD (Vrecenak et al.,
2014b). Intraperitoneal injection was compared to intracardiac
delivery and the latter achieved far higher intravascular lev-
els of circulating donor cells, higher levels of initial fetal liver
engraftment, and subsequent higher long term donor chimerism.
Donor-derived renal grafts were transplanted and monitored for
rejection to assess the presence of donor specific chimerism vs.
tolerance. All recipients with chimerism above 10% showed no
acute or chronic rejection at any point and, importantly, no signs
of GVHD were observed, further underlining that fetal recipients
are less prone to the development of this serious complication.
Taken together, these experiments provide important experimen-
tal justification to move forward with clinical trials of IUHCT for
inherited hematologic diseases.
REJECTION BY MATERNAL MECHANISMS
Maternal antibodies in utero and in breast milk
Maternal immunoglobulin G (IgG) antibodies are transported to
the placenta via an FcR-mediated process (Malek et al., 1996).
The amount of maternal antibody present in the fetal blood-
stream increases exponentially during gestation, reaching 50% of
maternal blood levels at weeks 28–33, then continues to increase,
resulting in higher amounts of IgG in fetal thanmaternal serum at
term (Malek, 2003; Esposito et al., 2012). This maternal antibody
protects the baby in the first months of life, and maternal vac-
cination during pregnancy with the goal of protecting the infant
by transplacental IgG transfer has been demonstrated in clinical
trials (Esposito et al., 2012). After birth, maternal antibodies are
continuously transferred via breast milk and thus provide contin-
uous protection. Potential danger posed to fetuses by maternal
antibodies first became evident when fetal hemolytic anemia,
resulting from maternal anti-Rhesus antibodies was discovered
(Chown, 1954).
In IUHCT, maternal anti-donor antibodies have been shown
to play an important role in long-term chimerism maintenance:
Merianos et al. demonstrated that maternal sensitization during
IUHCT and subsequent transfer of alloantibodies via maternal
breast milk induces an adaptive immune response in mouse pups
which leads to graft rejection (Merianos et al., 2009). This rejec-
tion was not observed if the pups were fostered by dams not
subjected to the IUHCT procedure and thus did not produce
alloantibodies. In contrast to traditional views that suggest mater-
nal antibodies act by directly binding the target antigen, the
authors convincingly demonstrate the elicitation of a fetal effector
response, similar to observations by others in the setting of fetal
antibody exposure (Greeley et al., 2002; Setiady et al., 2003). The
maternal alloantibodies produced in this setting were both IgM
and IgG (mostly IgG2a) classes. Although the specific mechanism
by which maternal alloantibodies elicit an immune response in
the fetus is not yet clear, these observations suggests that maternal
sensitization during IUHCT in humans could pose an additional
hurdle as the gestation time in humans is much longer, potentially
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allowing for transplacental IgG alloantibody transport that can-
not be avoided (in contrast to breast milk-related alloantibody
exposure).
Maternal microchimerism
Many maternal cell types contribute to microchimerism of the
fetus; cells of myeloid and lymphoid lineages have been identi-
fied as well as hematopoietic progenitors (Jonsson et al., 2008).
Though maternal microchimerism represents a low percentage
of total fetal immune cells, it is potentially relevant for IUHCT.
In cord blood, 0.1–0.5% of total T cells are maternal (Hall et al.,
1995;Mold et al., 2008). Thesematernal cells are enriched for cells
specific for antigens inherited by the fetus from the father, and
can enhance graft-vs.-leukemia effects if the cord-blood recip-
ient shares them (Burlingham and Benichou, 2012). In turn,
these maternal cells can elicit rejection responses if the HSC
graft carries paternal antigen or other antigens to which mater-
nal cells have been sensitized (Figure 1). To avoid graft rejection
caused by maternal chimeric cells, a maternal transplant source
or avoidance of paternal inherited antigens is advantageous. MLR
detection of preexisting maternal reactivity to a potential HSC
donor can help identify such potential rejection responses.
Maternal cells with anti-donor specificity can also directly
inhibit the establishment of chimerism in IUHCT (Nijagal et al.,
2011). In these experiments, T or B cell deficient dams were bred
to wild-type fathers and the fetuses were subjected to IUHCT.
Engraftment was significantly improved in dams lacking T cells
but not B cells. This improvement was not observed if the graft
matched the MHC of the mother suggesting that for initial
engraftment, transplacental trafficking of maternal allospecific
T cells poses a substantial barrier. Whether these maternal cells
directly kill donor cells or whether the loss of chimerism is due to
other mechanisms is currently unclear. Additionally, the authors
demonstrated a marked increase in maternal T cell and also B cell
trafficking to the fetus after IUHCT of allogeneic cells (compared
to control pups receiving PBS). Potentially, the presence of the
additional antigenic load from the donor cells or the induction
of local inflammatory responses to cellular debris or transferred
apoptotic cells that confer danger signals attracts more maternal
cells.
Altered maternal fetal cellular trafficking in humans has been
reported after fetal surgeries, preeclampsia and pregnancy termi-
nation but potential roles for these insults in the limitation of
chimerism has not been determined (Jeanty et al., 2014).
CONCLUSION
The fetal immune system is a complex system that changes
dramatically as a function of developmental stage, and to pat-
terns of exposure to alloantigens. Given that direct query of the
immune response after IUHCT is difficult, well-designed in vitro
and in vivo experiments are needed to dissect the mechanisms
of tolerance and rejection for this potentially important clinical
procedure.
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